Abiraterone acetate not checked
Janssen Research & Development, LLC
FollowEvery change as it happens, and a Monday email
Trials
16 active
23 in total · 13 in the EU
What this is
- How it works
- Cytochrome P450 17A1 Inhibitor FDA class
- How it’s given
- “Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.”In the company’s words, NCT02257736 on ClinicalTrials.gov
- Tested for
- Prostatic Neoplasms (4 trials), Castration-Resistant Prostatic Cancer, Prostatic Neoplasms, Castration-Resistant, Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Main trialPhase 3
- “The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy \[treatment of cancer using drugs\]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland \[gland that makes fluid that aids movement of sperm\]).”In the company’s words, NCT02257736 on ClinicalTrials.gov
- Other names
- Zytiga
Other drugs for Prostatic Neoplasms
- ApalutamideJanssen Research & Development, LLC · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
- Aglatimagene besadenovecCandel Therapeutics · Phase 3
Coming up2
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 19 Mar 2018 | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 3Active, not recruiting | 8 Oct 2021 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | |
| Phase 3Active, not recruiting | 7 Jan 2025 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) | |
| Phase 2Active, not recruiting | 31 Aug 2021 | A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Active, not recruiting | 27 Jun 2016 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Active, not recruiting | 15 Oct 2021 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | |
| Phase 1Active, not recruiting | 31 Dec 2026 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | |
| Phase 1Recruiting | 31 Aug 2027 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | |
| Phase 4Completed | 31 Dec 2017 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | |
| Phase 3Completed | 31 Mar 2014 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 3Completed | 31 Oct 2016 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | |
| Phase 3Completed | 22 Apr 2021 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | |
| Phase 2Completed | 24 Dec 2013 | IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | |
| Phase 1Completed | 10 May 2014 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | |
| Phase 1Terminated | 30 Sep 2022 | A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 3Authorised | not given | Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial | |
| Phase 2Authorised | not given | Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST) | |
| Phase 3Authorised | not given | B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents | |
| Phase 3Authorised | not given | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) | |
| Phase 3Authorised | not given | ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | |
| Phase 4Authorised | not given | RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC) | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG | |
| Phase 4Authorised | not given | Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026